IBA develops, manufactures and supports medical devices and software solutions for cancer treatment by proton beam therapy, for cancer diagnosis and for patient quality assurance (Dosimetry). In addition, the company partners with healthcare leaders to provide cancer clinics and academic health centers with a fully-integrated approach of the patient flow.
Barcelona, Spain, October 16th, 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy and radiopharmacy solutions, today....
Louvain-la-Neuve, Belgium, 25th September 2016 - IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has signed a contract with Medstar (Shanghai) Leasing Co., Ltd, a subsidiary of Concord Medical Services Holdings Limited (“Concord Medical”), for the purchase, installation and maintenance of a proton therapy system. The system will be installed at Beijing Proton Medical Center and be operated by Beijing Proton Medical Center Limited.
IBA has signed a contract with Proton Partners International (PPI) to install a Proteus®ONE* compact proton therapy solution in a private clinic in Abu Dhabi, UAE.
Louvain-la-Neuve - 6 September 2016 - IBA (Ion Beam Applications S.A.), the world leader in proton therapy solutions for cancer treatment, is celebrating its 30th anniversary.
IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer and RaySearch Laboratories, the global leader in treatment planning software, have entered into a long-term strategic alliance to combine their respective technologies and advance adaptive proton therapy.